Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A composition for adjuvant treatment of chronic bleeding and its application

A technology of adjuvant therapy and composition, applied in the field of cell biology, molecular biology and drug research and development, can solve the problems of no particularly effective treatment method, high cost, short-term effect, etc., to avoid infection or immune rejection, and easy to use , long-lasting effect

Active Publication Date: 2021-02-26
广州市天河诺亚生物工程有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there is no particularly effective clinical treatment for chronic bleeding, and the treatment for acute massive bleeding, such as platelet transfusion, is excessive medical treatment for chronic bleeding diseases, the cost is too high and the effect is short

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A composition for adjuvant treatment of chronic bleeding and its application
  • A composition for adjuvant treatment of chronic bleeding and its application
  • A composition for adjuvant treatment of chronic bleeding and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] According to different indications, MKPC and EPC exosomes are mixed in different proportions to obtain pharmaceutical preparations for adjuvant treatment of chronic bleeding. MKPC with 1*10 5 The MKPC solution obtained by dissolving 1 cell in 1 mL of normal saline is 1 unit of MKPC, and the EPC exosomes are used per 1*10 5 The EPC solution obtained by dissolving the exosomes (0.1-0.18 μg) extracted by EPC in 1 mL of normal saline is 1 unit of EPC exosomes. For different chronic bleeding conditions, different proportions of MKPC solution and EPC should be combined. The solution is the drug preparation for adjuvant therapy in a total volume of 4 mL. The details are shown in Table 1.

[0035] Table 1 MKPC and EPC exosome content ratio (calculated by volume) in the composition of different indications

[0036]

Embodiment 2

[0038] The gastric ulcer animal experiment of the pharmaceutical preparation of the above-mentioned Example 1 was taken, and the pharmaceutical preparation contained a volume ratio of 40% MKPC solution and a volume ratio of 60% EPC exosome solution.

[0039] Animal model of gastric mucosal injury: 24 healthy Wistar rats were randomly divided into control group, MKPC group, EPC exosome group and MKPC+EPC exosome group according to body weight.

[0040] The experimental acetic acid-induced gastric ulcer model in rats was prepared by acetic acid smearing method. The animal model was treated by intravenous infusion. The control group was infused with 4 mL of normal saline, and the MKPC group was infused with an equal amount of normal saline solution containing MKPC (that is, containing 4*10 5 normal saline solution of MKPC), the EPC exosome group was infused with the same amount of normal saline solution containing EPC exosome (that is, containing cultured 4*10 5 The normal sali...

Embodiment 3

[0047] The intestinal ulcer animal experiment of the pharmaceutical preparation of the above-mentioned Example 1 was taken, and the pharmaceutical preparation contained a volume ratio of 70% MKPC solution and a volume ratio of 30% EPC exosome solution.

[0048] Ulcerative colitis animal model: 32 healthy Wistar rats were randomly divided into control group, MKPC group, EPC exosome group and MKPC+EPC exosome group according to body weight.

[0049] An experimental rat intestinal ulcer model was prepared by using 50% ethanol solution containing 150mg / kg trinitrobenzenesulfonic acid (TNBS). The animal model is treated by intravenous infusion, the treatment period is 7 days, by PGE 2 The detection identifies the outcome of the treatment. The control group was infused with 4 mL of normal saline, and the MKPC group was infused with an equal amount of normal saline solution containing MKPC (that is, containing 4*10 5 normal saline solution of MKPC), the EPC exosome group was infuse...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a composition for adjuvant treatment of chronic bleeding and its application. The composition is composed of exosomes of megakaryocyte progenitor cells and endothelial progenitor cells, and can be formulated according to different indications, which is scientific and economical. The endothelial progenitor cell exosomes used in the present invention are obtained by ultra-high-speed centrifugation of the culture medium of the endothelial progenitor cells after the endothelial progenitor cells are cultured, and the endothelial progenitor cells with more clinical therapeutic value can be reserved for other severe diseases Diseases, more comprehensive use of biological resources; the composition of the present invention is used for adjuvant treatment of chronic bleeding, taking into account blood coagulation and blood vessel repair, avoiding infection or immune rejection caused by blood transfusion, lower cost, safer, better curative effect, It is more durable and has important clinical application value.

Description

technical field [0001] The invention belongs to the technical fields of cell biology, molecular biology and drug research and development, and specifically relates to a composition for adjuvant treatment of chronic bleeding and its application. Background technique [0002] Chronic bleeding disorders caused by various reasons, such as: visceral ulcer bleeding, hematuria, hematochezia, dysfunctional uterine bleeding, traumatic bleeding, etc., are clinical common and frequently-occurring diseases, with complex etiology and rapid pathogenesis transformation. Long-term chronic bleeding can cause a series of chain reactions such as anemia, malnutrition, and decreased body resistance, seriously affecting people's physical and mental health. [0003] For patients with chronic bleeding diseases, the loss of platelets is far more serious than that of healthy bodies. Because the blood loss process is slow and continuous, it is quite different from acute blood loss caused by trauma or ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K35/44A61K35/28A61P7/04
CPCA61K35/28A61K35/44A61P7/04A61K2300/00
Inventor 魏伟嵐山芮袁嘉恩
Owner 广州市天河诺亚生物工程有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com